lazertinib | Lazertinib: First Approval

Keyword	CPC	PCC	Volume	Score	Length of keyword
lazertinib	1.01	0.5	221	59	10

Keyword	CPC	PCC	Volume	Score
lazertinib	1.89	0.6	9428	53
lazertinib fda approval	0.43	0.9	5076	17
lazertinib amivantamab	1.35	0.1	2788	36
lazertinib janssen	0.31	0.1	625	49
lazertinib fda	0.25	0.5	8308	52
lazertinib vs osimertinib	0.58	1	3801	91
lazertinib brand name	0.77	0.4	475	32
lazertinib mechanism of action	0.4	0.3	2682	47
lazertinib phase 3	1.6	0.9	1191	65
lazertinib fda label	0.84	0.9	5026	63

Search Results related to lazertinib on Search Engine

Lazertinib: First Approval - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/34028784/

WebLazertinib (LECLAZA ®) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mutation and activating EGFR mutations Ex19del ...

DA: 41 PA: 48 MOZ Rank: 90

Lazertinib Versus Gefitinib as First-Line Treatment in Patients …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.23.00515

WebJun 28, 2023 · Lazertinib is a potent, CNS-active, mutant-selective, third-generation TKI that targets T790M and sensitizing mutations while sparing wild-type EGFR. 8 Although both lazertinib and osimertinib form irreversible covalent bonds to C797, lazertinib is distinguished by its substituted pyrazole and morpholine groups and is more selective for …

DA: 18 PA: 26 MOZ Rank: 84

Lazertinib: First Approval - PMC - National Center for …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217052/

WebMay 24, 2021 · Lazertinib (LECLAZA ®) is an oral, third-generation, EGFR-TKI being developed by Yuhan and Janssen Biotech for the treatment of NSCLC. It is a brain-penetrant, irreversible EGFR-TKI that targets the EGFR T790M mutation and the activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR.

DA: 71 PA: 4 MOZ Rank: 87

Lazertinib Demonstrates Significant Efficacy Improvement
esmo.org

https://www.esmo.org/oncology-news/lazertinib-demonstrates-significant-efficacy-improvement-compared-with-gefitinib-in-the-first-line-treatment-of-egfr-mutated-advanced-nsclc

WebJul 17, 2023 · Lazertinib is a potent, central nervous system (CNS) active, mutation selective, third generation TKI that targets T790M and sensitising mutations while sparing wild-type EGFR. Preclinical studies demonstrated several potential differentiators of lazertinib over osimertinib.

DA: 97 PA: 28 MOZ Rank: 47

Janssen Announces New Data Supporting Safety and Efficacy of …
jnj.com

https://www.jnj.com/media-center/press-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations

WebJul 26, 2022 · Lazertinib is an oral, third-generation, brain-penetrant, EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. Interim safety and efficacy results from the lazertinib Phase 1/2 study were published in The Lancet Oncology in 2019.

DA: 89 PA: 3 MOZ Rank: 65

Lazertinib: on the Way to Its Throne - PMC - National Center for
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424779/

WebAug 18, 2022 · Lazertinib is an oral, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that forms an irreversible covalent bond to the Cys797 residue in the ATP-binding site of the EGFR kinase domain and exhibits a high selectivity for sensitizing and T790M EGFR mutations.

DA: 21 PA: 1 MOZ Rank: 38

Phase 3 MARIPOSA-2 Study Shows RYBREVANT
jnj.com

https://www.jnj.com/media-center/press-releases/phase-3-mariposa-2-study-shows-rybrevant-amivantamab-vmjw-plus-chemotherapy-given-with-or-without-lazertinib-reduced-risk-of-disease-progression-or-death-by-56-and-52-percent-respectively-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-who-progressed-on-or-after-osimertinib

WebOct 23, 2023 · Specifically, RYBREVANT ® plus chemotherapy and RYBREVANT ® plus chemotherapy and lazertinib reduced the risk of intracranial progression or death by 45 percent and 42 percent, respectively compared to chemotherapy alone (HR=0.55; 95 percent CI, 0.38–0.79; P =0.001 and HR=0.58; 95 percent CI, 0.44–0.78; P <0.001, …

DA: 44 PA: 83 MOZ Rank: 21

Amivantamab plus lazertinib in osimertinib-relapsed - Nature
nature.com

https://www.nature.com/articles/s41591-023-02554-7

WebSep 14, 2023 · In this open-label, dose-escalation and dose-expansion phase 1 trial, the potential for improved anti-tumor activity by combining amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a...

DA: 76 PA: 2 MOZ Rank: 89

Lazertinib Demonstrates Significant PFS Improvement in Advanced
ascopubs.org

https://dailynews.ascopubs.org/do/lazertinib-demonstrates-significant-pfs-improvement-advanced-egfr--mutated-nsclc

WebNov 1, 2023 · Dr. Byoung Chul Cho. Key Points: In LASER-301, lazertinib significantly improved progression-free survival (PFS) compared with gefitinib in the first-line treatment of EGFR -mutant advanced non–small cell lung cancer (NSCLC). Median PFS was 20.6 vs 9.7 months and median duration of response was 19.4 vs 8.3 months for lazertinib and …

DA: 3 PA: 14 MOZ Rank: 60

Lazertinib: First Approval | Drugs - Springer
springer.com

https://link.springer.com/article/10.1007/s40265-021-01533-x

WebMay 24, 2021 · Lazertinib (LECLAZA ®) is an oral, third-generation, EGFR-TKI being developed by Yuhan and Janssen Biotech for the treatment of NSCLC. It is a brain-penetrant, irreversible EGFR-TKI that targets the EGFR T790M mutation and the activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR.

DA: 11 PA: 22 MOZ Rank: 66